Committee backs J&J CAR-T but redirects price negotiation with four-year proposal

"We disagree with many of the assertions made by the Committee and will continue to work in the interests of myeloma patients who have exhausted four or more lines of treatment," said a Johnson & Johnson spokesperson. …